ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 74 citations in OpenAlex.
- Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.Journal of neuro-oncology · 2024Trial
- Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.Neuro-oncology · 2014Trial
- Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.Neuro-oncology · 2012Trial
- Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN-Associated and Sporadic NF2-Deficient Meningiomas.Cancer research communications · 2026Article
- Mapping the Somatic Mutation Landscape of Familial NF2-Related Schwannomatosis using Whole-Exome Sequencing.International journal of medical sciences · 2025Article
- Brain and/or Spinal Cord Tumors Accompanied with Other Diseases or Syndromes.Advances in experimental medicine and biology · 2023Article
- Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma.Molecular cancer therapeutics · 2021Article
- Article
- Article
- Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2017Article
- Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.Neuro-oncology · 2016Review
- A neuronal function of the tumor suppressor protein merlin.Acta neuropathologica communications · 2014Review
- mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.Neuro-oncology · 2014Article
- NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.Oncotarget · 2014Review
- Advances in the treatment of neurofibromatosis-associated tumours.Nature reviews. Clinical oncology · 2013Review
- Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features.Neuro-oncology · 2012Article
- Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.Journal of neurosurgery · 2012Article
- Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012Article
- Treatment of vestibular schwannoma cells with ErbB inhibitors.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 6 institutions in 3 countries.
Funding
Abstract
purposeNeurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder associated primarily with bilateral schwannomas seen on the superior vestibular branches of the eighth cranial nerves. Significant morbidity can result from surgical treatment of these tumors. Meningiomas, ependymomas, and other benign central nervous system tumors are also common in NF2. The lack of effective treatments for NF2 marks an unmet medical need. EXPERIMENTAL
designHere, we provide recommendations from a workshop, cochaired by Drs. D. Gareth Evans and Marco Giovannini, of 36 international researchers, physicians, representatives of the biotechnology industry, and patient advocates on how to accelerate progress toward NF2 clinical trials.
resultsWorkshop participants reached a consensus that, based on current knowledge, the time is right to plan and implement NF2 clinical trials. Obstacles impeding NF2 clinical trials and how to address them were discussed, as well as the candidate therapeutic pipeline for NF2.
conclusionsBoth phase 0 and phase II NF2 trials are near-term options for NF2 clinical trials. The number of NF2 patients in the population remains limited, and successful recruitment will require ongoing collaboration efforts between NF2 clinics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.